Foresite Capital Management VI
WEST HOLLYWOOD, CAfiles as Foresite Capital Management VI LLC
$643m in 23 US stocks at the end of 30 June 2026. The top 10 are 81.5% of the money. It changed about 26.1% of the portfolio this quarter.
Value
$643m
Stocks
23
Top 10 share
81.5%
Turnover
26.1%
What changed this quarter
New
Bought for the first time this quarter.
- Seaport TherapeuticsSPTX6.0% of the fund
- Parabilis MedicinesPBLS4.3% of the fund
- Beam TherapeuticsBEAM1.8% of the fund
- ArriVent BioPharmaAVBP1.6% of the fund
- Aura BiosciencesAURA1.5% of the fund
- Research Alliance Corp IIIRACC0.5% of the fund
- Kailera TherapeuticsKLRA0.1% of the fund
- Disc MedicineIRON<0.1% of the fund
Added
Bought more of a stock they already held.
- CG OncologyCGON26.2% of the fund+7%
- Denali TherapeuticsDNLI5.6% of the fund+15%
- Celldex TherapeuticsCLDX5.1% of the fund+178%
- Agios PharmaceuticalsAGIO4.5% of the fund+50%
- GH ResearchGHRS3.9% of the fund+198%
- Jade BiosciencesJBIO3.1% of the fund+177%
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- OnKure TherapeuticsOKUR-100%
Holdings
- Seaport TherapeuticsSPTX
- Share
- 6.0%
- Value
- $39m
- Shares
- 1,779,521
New
- Parabilis MedicinesPBLS
- Share
- 4.3%
- Value
- $27m
- Shares
- 999,044
New
- AtaiBeckleyATAI
- Share
- 2.3%
- Value
- $14m
- Shares
- 2,750,000
Held
- Crinetics PharmaceuticalsCRNX
- Share
- 1.2%
- Value
- $8m
- Shares
- 212,010
Held
- Research Alliance Corp IIIRACC
- Share
- 0.5%
- Value
- $3m
- Shares
- 300,000
New
- Kailera TherapeuticsKLRA
- Share
- 0.1%
- Value
- $826,125
- Shares
- 37,500
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| CG OncologyCGON | 26.2% | $168m | 2,369,574 | +7% |
| AlumisALMS | 18.6% | $120m | 4,247,670 | Held |
| Seaport TherapeuticsSPTX | 6.0% | $39m | 1,779,521 | New |
| Denali TherapeuticsDNLI | 5.6% | $36m | 1,396,771 | +15% |
| Celldex TherapeuticsCLDX | 5.1% | $33m | 879,713 | +178% |
| Agios PharmaceuticalsAGIO | 4.5% | $29m | 785,000 | +50% |
| Corvus PharmaceuticalsCRVS | 4.3% | $27m | 1,831,233 | Held |
| Parabilis MedicinesPBLS | 4.3% | $27m | 999,044 | New |
| GH ResearchGHRS | 3.9% | $25m | 940,493 | +198% |
| Jade BiosciencesJBIO | 3.1% | $20m | 886,667 | +177% |
| Hinge HealthHNGE | 2.8% | $18m | 220,400 | Held |
| Kymera TherapeuticsKYMR | 2.6% | $17m | 146,332 | Held |
| AtaiBeckleyATAI | 2.3% | $14m | 2,750,000 | Held |
| VerastemVSTM | 1.9% | $12m | 3,146,631 | Held |
| Beam TherapeuticsBEAM | 1.8% | $11m | 330,000 | New |
| Minerva NeurosciencesNERV | 1.7% | $11m | 1,985,584 | Held |
| ArriVent BioPharmaAVBP | 1.6% | $10m | 301,341 | New |
| Aura BiosciencesAURA | 1.5% | $9m | 1,333,334 | New |
| Crinetics PharmaceuticalsCRNX | 1.2% | $8m | 212,010 | Held |
| Research Alliance Corp IIIRACC | 0.5% | $3m | 300,000 | New |
| Zura BioZURA | 0.4% | $3m | 450,000 | Held |
| Kailera TherapeuticsKLRA | 0.1% | $826,125 | 37,500 | New |
| Disc MedicineIRON | <0.1% | $70,946 | 970 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 261.2% since 30 June 2025.
Where the money is
Health care97.2%
Technology2.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.